Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-lactam cholesterol absorption inhibitors.

Duane A Burnett1

  • 1Discovery Chemistry-CNS/CV, Schering-Plough Research Institute, 2015 Galloping Hill Rd., MS 2800, Kenilworth, NJ 07033, USA. duane.burnett@spcorp.com

Current Medicinal Chemistry
|July 29, 2004
PubMed
Summary

Beta-lactams are effective cholesterol absorption inhibitors (CAIs). Research details their discovery, synthesis, and development into ezetimibe, a potent hypolipidemic agent for managing cholesterol levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and characterization of novel TRPML1 agonists.

Bioorganic & medicinal chemistry letters·2023
Same author

Discovery of oxazoline enhancers of cellular progranulin release.

Bioorganic & medicinal chemistry letters·2022
Same author

Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator.

Journal of medicinal chemistry·2021
Same author

Discovery of quinuclidine modulators of cellular progranulin.

Bioorganic & medicinal chemistry letters·2021
Same author

Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease.

Journal of medicinal chemistry·2017
Same author

Design and synthesis of water soluble β-aminosulfone analogues of SCH 900229 as γ-secretase inhibitors.

Bioorganic & medicinal chemistry letters·2016

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Cardiovascular Research

Background:

  • Beta-lactams have emerged as potent inhibitors of cholesterol absorption.
  • Cholesterol absorption inhibitors (CAIs) represent a significant class of hypolipidemic agents.
  • Understanding the structure-activity relationships (SAR) is crucial for developing effective drugs.

Purpose of the Study:

  • To describe the discovery, SAR, and synthesis of beta-lactam-based CAIs.
  • To introduce ezetimibe (Sch 58235) as a second-generation clinical candidate.
  • To present preclinical and clinical data for ezetimibe, including combination therapy with statins.

Main Methods:

  • Asymmetric synthesis of beta-lactam derivatives.
  • Metabolism studies to identify active metabolites.

Related Experiment Videos

  • Preclinical and early clinical trial evaluations.
  • Development of conformationally constrained analogs for pharmacophore modeling.
  • Biochemical studies to elucidate the mechanism of action.

    • Main Results:

    • Identification and synthesis of potent beta-lactam CAIs.
    • Development of ezetimibe, a highly efficacious second-generation agent.
    • Demonstration of ezetimibe's efficacy in monotherapy and combination with statins.
    • Creation of biochemical tools for studying cholesterol uptake pathways.

    Conclusions:

    • Beta-lactams represent a valuable class of cholesterol absorption inhibitors.
    • Ezetimibe is a clinically validated and effective agent for lowering cholesterol.
    • Pharmacophore modeling and mechanism of action studies continue to advance CAI research.